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The histrelin implant (Supprelin LA) is an efﬁcacious, safe and well tolerated medication for the treat-
ment of central precocious puberty (CPP). Minor reactions such as bruising, redness, and pain at the
implant site have commonly occurred, but only two cases of systemic allergic reaction leading to
emergent removal of device have previously been reported. An otherwise healthy eleven-year-old female
with CPP and no history of prior supprelin implantation, and a nine-year-old female with CPP and history
of two prior supprelin implantations without complications, had a supprelin implant inserted on the
same day. Within days of the procedure both presented with severe allergic reaction and underwent
removal of the device. A few months after removal, both children had another supprelin implant placed
without complications. It was determined that the device was not the cause of the allergic reaction, but
rather the dressing material included in the implantation kit that was the offending agent. This report
describes two patients with a severe systemic allergic reaction after histrelin implant necessitating ur-
gent implant removal with resolution of allergic symptoms. It was later determined that the allergic
reaction was caused by a substance in the self-adhering dressing wrap.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Central precocious puberty (CPP) is deﬁned as puberty occurring
prior to the age of seven and a half to eight years in girls and nine
years in boys. The incidence of CPP is higher in girls and is usually
idiopathic. Although experts have not been able to agree on one
deﬁnitive cause, they have noted some possible contributing factors
including high body mass index, stress, chemicals such as phtha-
lates found in many household products, and hormones in food [1].
The main goals of treatment include the arrest of pubertal pro-
gression and preservation of ﬁnal adult height. Gonadotropin-
releasing hormone agonists for the treatment of CPP have been the
standard of care worldwide for approximately twenty years, but in
the United States this typically involved monthly painful intra-
muscular injections [1].
The histrelin implant is an exciting new alternative to the
standard monthly injections as it can promote slow release for one
year and avoids the inconvenience of monthly dosing. The histrelin
implant is placed and removed using either general anesthesia or
local anesthesia depending on the age andmaturity of the child. In a
study by Rahhal et al., the histrelin implant demonstrated profound
suppression of gonadotropin and sex-steroid production for oneospital, Division of Pediatric
2, USA.
onnelly).
Inc. This is an open access article uyear in children with CPP and was well tolerated. It was also found
that bone age advancement as well as growth velocity decreased
signiﬁcantly with treatment using histrelin implants [2].
This report discusses two patients who developed severe
allergic reactions shortly after supprelin implantation and under-
went urgent removal of the device within one week after place-
ment. These adverse reactions were reported to the manufacturer
of the supprelin implants and it was later discovered that a sub-
stance in the self-adhering dressing wrap in the implantation kit
caused the allergic reaction. This was a product by a different
manufacturer that had replaced the original product. This same
month a subset of implantation administration kits were recalled,
and the original dressing product replaced it with no history of
reported adverse reactions [3].
1. Case summary
1.1. Patient 1
An eleven-year-old female presented with central precocious
puberty, asthma and short stature. Her growth hormone levels
were normal, but her bone age was slightly advanced. She has had
no prior hormonal therapy. A histrelin implant was placed under
general anesthesia in the subcutaneous tissue of the left upper
extremity. A self-adhering dressing wrap included in the insertionnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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patient presented with a pruritic rash that started on the left arm at
the location of the implantation and spread to the entire left arm, as
well as the ipsilateral side of her face and trunk. Diphenhydramine
and prednisone were prescribed but the rash worsened. Following
discussion between medical staff and family, a decision was made
to remove the histrelin implant. The histrelin implant was sent to
the pathology lab and saved in preparation to send to the manu-
facturer for analysis. The allergic symptoms cleared within one
week. Four months later, the patient had a new histrelin implant
placed into the left upper arm, uneventfully. An elasticized bandage
was used instead of the self-adhering dressing wrap provided in the
implantation kit. Since this new implantation the patient has had
no signs of an allergic reaction.
1.2. Patient 2
A nine-year-old otherwise healthy female with central preco-
cious puberty had low growth hormone levels and short stature
since early childhood. Two prior histrelin implants were placed
without complications. Her third histrelin implant was inserted in
the left upper arm under general anesthesia. A self-adhering
dressing wrap was used as a pressure dressing. Several days after
the implant insertion, the patient presented with a pruritic
erythematous rash at the insertion site. Diphenhydramine and
prednisolone were prescribed, but the rash continued to worsen
and spread to the entire left side of her body. She had no viral
symptoms, dietary changes or skin product changes to explain the
allergic reaction. She was taken to the operating room that same
day for implant removal. The allergic symptoms cleared within one
week. The implant was sent to the pathology lab and was saved in
preparation to send to the manufacturer for analysis. Two months
later, the patient had a new histrellin implant placed into the left
upper arm, uneventfully. An elasticized bandage was used instead
of the self-adhering dressing wrap provided in the implantation kit.
Since this new implantation the patient has had no signs of an
allergic reaction.
2. Discussion
The histrelin implant (supprelin implant by Supprelin LA) was
introduced in 2007 and has proven to be efﬁcacious with a good
safety proﬁle and few side effects [2,4]. Studies have revealed that
the histrelin implant is equally as effective and safe for patients
receiving a second implant with removal of the ﬁrst after one year
of treatment [5]. Furthermore the histrelin implant reduces the
inconvenience of monthly injection dosing and may therefore
improve long-term compliance.
Previous studies have revealed the fairly common occurrence of
implant site reactions, such as bruising or pain, though the majority
of these reactions were mild and resolved without therapy within
one to two weeks. In a study conducted by Eugster et al., 50% of 36
patients reported mild site reactions [2]. An additional study con-
ducted by Rahhal et al., which involved patients receiving a second
year of therapy after a successful twelve months with the implant,
found that minor implant site reactions including bruising or pain
occurred in 61% percent of patients immediately after implant
placement [5].
While implant removal in response to adverse reactions is rare,
there have been a few reported cases. Miller and Shuklah reported
two cases where abscess formation in response to the histrelin
implants resulted in the necessity for removal of the device [6].
Fracture of the implant during surgical withdrawal has also been
reported, often necessitating sonographic imaging to localize the
implant to complete removal [7]. Davis et al. described two cases ofchildren requiring removal of the histrelin implant due to a sys-
temic allergic reaction characterized by generalized rash and severe
pruritus refractory to medical therapy. In both cases, the devices
were placed within days of each other and were from the same
manufacturer’s lot. In addition, they also reported three other
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kit, one that spontaneously resolved and two that responded to
medical management; none required device removal. Davis et al.
reported these adverse effects to the manufacturer, but received a
letter back from the manufacturer that no related cases had been
documented [8].
Our two patients had a severe systemic allergic reaction re-
fractory to medical management that ultimately underwent
implant removal. It was later discovered by the manufacturer that
the self-adhering dressing wrap included in the implantation kit
and not the device itself caused the allergic reaction. Of note, two
other children had histrelin implants placed at the hospital on the
same day by the same surgeon but did not develop any allergic or
adverse reaction, which leads to the assumption that some chil-
drenmay have an allergic predisposition to a particular material in
the adhesive wrap. It has been determined that certain Supprelin
LA implantation kits may contain cohesive bandage containing a
gum ester/resin-based natural material instead of synthetic
material [3].
3. Conclusion
This report describes two patients with a severe allergic reac-
tion following histrelin device implantation, ultimately leading to
the removal of the device within one week after placement. It waslater discovered that the self-adhering dressing wrap included in
the implantation kit, rather than the device itself caused the
reaction. As a result the implantation kits were recalled and a
different material, with no history of adverse reactions, was
substituted.
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